ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag

The Institute for Clinical and Economic Review (ICER) concluded Tuesday that gene therapies for hemophilia A and B are worth it even at a hefty lifetime cost of $2.5 million.

ICER's findings are outlined in a draft evidence report, which evaluated the efficacy and economic value of upcoming gene therapies for hemophilia A and B against existing treatment regimens.